BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Creditor Rights Coalition - ECPv6.4.0.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://creditorcoalition.org
X-WR-CALDESC:Events for Creditor Rights Coalition
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250409T110000
DTEND;TZID=America/New_York:20250409T110000
DTSTAMP:20260524T184711
CREATED:20250406T074847Z
LAST-MODIFIED:20250406T074847Z
UID:5362-1744196400-1744196400@creditorcoalition.org
SUMMARY:CreditSights: Inside Bausch Health’s Big Move: New Debt\, Old Risks
DESCRIPTION:Bausch’s $7.4 billion refinancing addresses near-term maturities and ends a five-year-long spinoff effort. However\, the operational picture hasn’t changed; it still faces the loss of exclusivity of its crown jewel drug and EBITDA generator\, Xifaxan\, in 2028\, along with a $4 billion maturity wall. This transaction extends the runway but doesn’t change the restructuring risks down the road. So\, what do the next few years look like\, and what options has this deal unlocked for the levered issuer?
URL:https://creditorcoalition.org/event/creditsights-inside-bausch-healths-big-move-new-debt-old-risks/
END:VEVENT
END:VCALENDAR